Report on Investigational Agent SCTB-14: A Bispecific PD-1/VEGF Antibody

Executive Summary

SCTB-14 is an intravenously administered, investigational bispecific antibody developed by the Chinese biopharmaceutical company Sinocelltech Group Ltd..[1] As a new molecular entity, it is engineered to simultaneously target two clinically validated pathways in oncology: the immune checkpoint receptor Programmed cell death protein 1 (PD-1) and the pro-angiogenic factor Vascular Endothelial Growth Factor (VEGF).[2] This dual mechanism of action is designed to exert a synergistic anti-tumor effect by concurrently reactivating the patient's T-cell-mediated immune response against cancer cells and inhibiting the formation of new blood vessels that tumors require for growth and metastasis.[1]

The clinical development program for SCTB-14 is advancing rapidly, with a clear strategic focus on non-small cell lung cancer (NSCLC), a leading cause of cancer mortality worldwide. The program is headlined by a pivotal Phase 3 trial in China (CTR20250935) evaluating SCTB-14 plus chemotherapy in patients with EGFR-mutated NSCLC who have progressed on prior tyrosine kinase inhibitor (TKI) therapy—a population with a significant unmet medical need.[2] Further underscoring its ambitious strategy in this indication, Sinocelltech is also planning a Phase 2/3 trial (CTR20251153) that will compare SCTB-14 plus chemotherapy directly against an established PD-1 inhibitor, tislelizumab, plus chemotherapy in the first-line treatment of driver gene-negative NSCLC.[2] Foundational safety and dose-finding studies, including a global Phase 1/2 trial (SCTB14-X101), are underway to support broader development across a range of advanced solid tumors.[4]